Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Immunovant, Inc. (Nasdaq: IMVT) announced that CEO Pete Salzmann will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:45 AM Eastern Time. The conference will showcase the company's focus on autoimmune diseases and the development of IMVT-1401 (batoclimab), a novel treatment aimed at managing conditions linked to pathogenic IgG antibodies. The presentation will be available via webcast on the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction – IMVT
In the trading session that priced this news, IMVT declined 0.37%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference, taking place January 10 - 13, 2022.
40th Annual J.P. Morgan Healthcare Conference
| Date: | Thursday, January 13th, 2022 |
| Time: | 9:45am Eastern Time |
| Webcast: | The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com |
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401 (batoclimab), a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Contact:
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com
